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Background
A large number of growth factors stimulate cell prolifera-
tion and/or differentiation by binding to and activating
membrane-spanning receptors that have intrinsic tyrosine
kinase activity in their cytoplasmic domains [1]. Ligand
binding induces receptor dimerization and auto-phospho-
rylation, creating high-affinity binding sites for down-
stream effector molecules. For example, phospholipase C
g (PLCg) can bind through its SH2 domain to receptors
that are activated by fibroblast growth factor (FGF),
epidermal growth factor (EGF), platelet-derived growth
factor (PDGF) and neurotrophin-3 (NT-3), and this
binding is required for phospholipid hydrolysis stimu-
lated by these factors [1–6]. Following ligand binding,
the FGF receptor (FGFR) becomes phosphorylated on
the tyrosine residue at position 766 (766Tyr), creating 
a high-affinity binding site for PLCg [7–9]. The
consequent phosphorylation and activation of PLCg
is reflected in an increased hydrolysis of phospholipids
that can be measured by the accumulation of inositol
phosphates (IPs) [8,9].
Phosphorylated peptides that correspond to the high-
affinity sites on the activated receptors are able to
compete, in vitro, for PLCg binding to the receptors
[1,7,10–14]. These results suggest that, provided they can
be delivered into cells, peptides corresponding to the
high-affinity PLCg binding sites from individual recep-
tors might serve as specific inhibitors of phospholipid
hydrolysis. A 16 amino-acid peptide corresponding to the
third helix of the homeodomain of the Antennapedia
protein can readily translocate across biological mem-
branes [15]; this translocation does not require energy and
does not appear to be receptor-mediated. Following con-
jugation, the third helix peptide has been shown to be
able to act as an internalization vector for other peptide
sequences, and it has been used recently to deliver a
pseudosubstrate peptide inhibitor of protein kinase C into
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Background: Activated receptor tyrosine kinases bind downstream effector
molecules with high affinity. Provided that they can be introduced into cells,
peptides corresponding to these high-affinity sites should be able to compete for
the interaction and thereby inhibit specific signal transduction cascades. The
high-affinity binding site for phospholipase C g (PLCg) on the activated fibroblast
growth factor receptor (FGFR) is centred around the tyrosine at position 766
(766Tyr), and peptides corresponding to this site inhibit PLCg binding to the
receptor in vitro. A 16 amino-acid peptide from the third helix of the
Antennapedia homeodomain protein has recently been shown to be able to act
as an internalization vector that can deliver other peptides into cells. Here, we
have designed a peptide that contains both the internalization sequence and the
FGFR high-affinity binding site for PLCg, and tested it in cultures of cerebellar
neurons for its ability to inhibit the activation of PLCg by basic FGF. 
Results: The peptide containing the FGFR high-affinity binding site for PLCg
inhibited phospholipid hydrolysis stimulated by basic FGF with a maximal effect
at 1 mg ml–1. Phosphorylation of 766Tyr was required for this effect. The
phosphorylated peptide had no effect on phospholipid hydrolysis stimulated by
platelet-derived growth factor, neurotrophin-3 and bradykinin. The
phosphorylated peptide also inhibited neurite outgrowth stimulated by FGF, but
had no effect on neurite outgrowth stimulated by agents that activate the FGFR
signal transduction cascade downstream from the activation of PLCg.
Conclusions: Cell-permeable peptides can be designed that inhibit the function
of receptor tyrosine kinases. In this context we have developed a peptide that
prevents the FGFR from activating PLCg, and have used this peptide to obtain
the first direct evidence that activation of PLCg is required for the neurite
outgrowth response stimulated by basic FGF.
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neurons [16]. We have designed a peptide that contains
the Antennapedia internalization sequence in tandem
with a nine amino-acid peptide corresponding to the high-
affinity PLCg-binding site on the activated FGFR. Here,
we report that, when phosphorylated on 766Tyr, this
peptide specifically inhibited the hydrolysis of phospho-
lipids stimulated by basic FGF; in contrast, the unphos-
phorylated peptide had no effect on this response. The
phosphorylated peptide also inhibited neurite outgrowth
stimulated by FGF, providing the first direct evidence
that PLCg activation is required for this response in
primary neurons. These data provide direct evidence that
the neurite outgrowth response to FGF requires activa-
tion of PLCg, and highlight the potential for developing a
novel family of peptide reagents to inhibit receptor-
effector interactions in vivo.
Results
A peptide corresponding to the FGF receptor PLCg-binding
site inhibits IP accumulation.
The mechanism whereby FGF activates PLCg is shown
schematically in Figure 1. In the present study, we wanted
to determine whether this response could be inhibited by
a peptide containing the Antennapedia internalization
sequence in tandem with a phosphorylated peptide corre-
sponding to the FGFR high-affinity binding site for PLCg
(called the 766Tyr-P peptide; see Fig. 1). We therefore cul-
tured small cerebellar granule cells from postnatal day 1
rats overnight before testing basic FGF for its ability to
stimulate PLCg activity as measured by the accumulation
of IPs (see Materials and methods for details). In an initial
set of experiments, we established that an increase in IP
accumulation could be detected within minutes of the
addition of the growth factor (data not shown), and that at
60 minutes a maximal response was induced by FGF at
100 ng ml–1 (Fig. 2). In parallel experiments, the test
peptide was added to the cultures for 60 minutes prior to
the addition of FGF as well as during the FGF treatment
step. In control cultures (no FGF), the 766Tyr-P peptide
had no effect on the basal accumulation of IPs measured,
even when present at up to 10 mg ml–1 (the measured
value being 97 ± 7 % of the control; mean ± SEM from
four independent experiments). In the presence of FGF, a
partial inhibition of the response was observed at
0.1 mg ml–1 of the 766Tyr-P peptide, with a total inhibition
at 1 mg ml–1 (Fig. 2).
The inhibition of IP accumulation suggested that the
766Tyr-P peptide had gained access to the cytoplasmic
compartment. In order to confirm this, the peptide was
biotinylated [17] and its uptake into cells monitored by
confocal microscopy, as described previously [15,16]. In
agreement with previous studies, we found that the
peptide had been taken up into the neurons and could be
localized by confocal microscopy to the cytoplasm of both
the cell body and the growth cone (Fig. 3).
Phosphorylation of 766Tyr in the FGFR is required for
PLCg binding. In order to determine whether phosphoryla-
tion of the peptide was essential to inhibit IP accumulation,
we repeated the experiments with an unphosphorylated
peptide; no inhibition of the FGF response was observed
when this peptide was used at up to 10 mg ml–1 (Fig. 2).
Specificity of the inhibitory peptide
In order to determine whether the 766Tyr-P peptide
specifically inhibited phospholipid hydrolysis stimulated
by FGF, we screened a number of other growth factors,
whose receptors are known to bind and activate PLCg, for
their effects on IP accumulation in cerebellar neurons.
PDGF [18], NT-3 [6,19,20], NGF [21] and EGF [2,3]
were tested at 1, 10 and 100 ng ml–1. After 60 minutes,
only PDGF and NT-3 had stimulated IP accumulation
(Fig. 4), and these responses were not inhibited by a maxi-
mally active concentration of the 766Tyr-P peptide (Fig. 4).
Figure 1
A schematic of the experimental paradigm. Following ligand binding the
FGFR becomes phosphorylated on 766Tyr and this creates a high affinity
binding site for PLCg. PLCg is in turn phosphorylated and activated by
the receptor, and as a result it hydrolyzes membrane phospholipids. The
products of this reaction are inositol phosphates (IPs) and diacylglycerol
(DAG). We have made a cell-permeable peptide that corresponds to
the FGFR high-affinity binding site for PLCg in tandem with a sequence
from the Antennapedia protein that has previously been shown to act as
an internalization vector. This peptide was tested for its ability to inhibit
PLCg activation by basic FGF.
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The bradykinin receptor is coupled to another PLC
isoform via a G-protein [22]. When cerebellar neurons
were stimulated with 1 mg ml–1 bradykinin, a significant
increase in accumulation of IPs was observed, and this
effect was also not inhibited by the 766Tyr-P peptide (Fig.
4). These data demonstrate an element of specificity in
the activity of the inhibitory peptide towards activation of
the PLCg by the FGF receptor, relative to at least two
other receptor tyrosine kinases.
The 766Tyr-P peptide inhibits neurite outgrowth stimulated
by basic FGF
In cells that overexpress transfected FGFRs, activation of
PLCg is not required for mitogenic responses stimulated
by FGF [8,9]. A large body of evidence suggests, however,
that this step is both necessary and sufficient to account
for the increase in neurite outgrowth from cerebellar
granule cells stimulated by this factor [23]. Over a 16 hour
culture period, a maximal increase in neurite outgrowth
can be induced by 5–10 ng ml–1 FGF [23]. Here, we found
that this response was partially inhibited by the 766Tyr-P
peptide at 0.1 mg ml–1, and fully inhibited at 1 mg ml–1
(Fig. 5). Again, it was essential that the peptide was phos-
phorylated on 766Tyr for this effect (Fig. 5). An almost full
inhibition of the FGF response could also be induced by
simply pre-treating the neurons with the 766Tyr-P peptide
prior to plating on the substratum and the addition of
FGF, providing further evidence that it is the peptide
within the cell that inhibits the response (Fig. 6). 
Diacylglycerol (DAG) is the other product of the hydroly-
sis of phospholipids by PLCg, and neurite outgrowth stim-
ulated by FGF can be blocked by a DAG lipase inhibitor
which prevents the hydrolysis of DAG and the subsequent
production of arachidonic acid [23]. FGF has been shown
to stimulate a DAG-lipase-sensitive increase in the levels
of arachidonic acid in cerebellar neurons [24]. Agents that
increase arachidonic acid levels in neurons, or the addition
of arachidonic acid itself, stimulate neurite outgrowth from
cerebellar neurons by activating the FGFR signal transduc-
tion cascade downstream of the FGFR–PLCg interaction
Figure 2
Stimulation of IP accumulation by basic FGF and inhibition by the
766Tyr-P peptide. Cultures of cerebellar granule cells were established
overnight before being washed and incubated for 60 min with control
media or media containing 100 ng ml–1 basic FGF. In parallel experi-
ments, the cultures were additionally treated with the phosphorylated
766Tyr-P peptide (766Y-P) at 0.1 mg ml–1 or 1 mg ml–1, or with the corre-
sponding unphosphorylated peptide (766Y) at 10 mg ml–1. The results
show the accumulation of IPs, expressed as a percentage of the control
value, determined in the given number of independent experiments. Bars
show the standard error of the mean (SEM). When tested at 10mg ml–1,
the peptides did not on their own affect the basal IP accumulation (mea-
sured values being 97 ± 7 % of control for the phosphorylated peptide
and 97 ± 12 % for the unphosphorylated peptide, both values mean ±
SEM from four independent experiments).
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Figure 3
Uptake of the 766Tyr-P peptide into neurons.
Representative examples of cerebellar
neurons were treated for 2 h with (a,b) the
biotinylated 766Tyr-P peptide or with (c) a
control biotinylated peptide that does not get
taken up into cells (see Materials and
methods for details). The cultures were
washed and permeabilized and the peptides
detected with FITC-conjugated streptavidin.
The micrographs show optical sections
through the cell which demonstrate that the
biotinylated 766Tyr-P can be localized to the
interior of the cell. In contrast, cells treated
with the control peptide were negative.
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[23]. In order to determine whether the 766Tyr-P peptide
was acting at the expected step in this cascade, we tested
its effect on the neurite outgrowth response stimulated by
arachidonic acid. At 10 mM, arachidonic acid stimulated
neurite outgrowth in a manner that was indistinguishable
from the response to FGF (Fig. 6); whereas the FGF
response was almost fully inhibited by pre-treating neurons
with the 766Tyr-P peptide, the response to arachidonic acid
was unaffected (Fig. 6). These experiments establish that
the peptide inhibits the neurite outgrowth response
upstream from the generation of arachidonic acid in the
FGFR signal transduction cascade, and show that the
peptide has no toxic or non-specific effects on neurons. A
similar neurite outgrowth response can also be induced by
melittin, potassium depolarisation and cholera toxin [23],
and these responses were also not inhibited by the
phosphorylated peptide (data not shown).
Discussion
The lack of specific inhibitors for many cellular inter-
actions precludes direct tests of their involvement in bio-
chemical and biological responses within living cells.
PLCg is a case in point, and to our knowledge there are no
available inhibitors of this key enzyme. In principle, pep-
tides corresponding to sites that are involved in the
binding of effectors to targets or substrates should be able
to compete for the interaction, and in this way inhibit
function. Such a strategy has been used to develop
pseudosubstrate-based peptide inhibitors of enzymes such
as protein kinase C [25]. The use of peptide inhibitors is
obviously limited by the ability to deliver the peptide into
cells, and also by the affinity of the peptide for its
intended target. Although peptides can be delivered into
cells by methods such as electroporation or microinjection,
these methods are not optimal in that it is difficult to get
Figure 4
Stimulation of IP accumulation by a range of
growth factors and the lack of effect of the
766Tyr-P peptide. Cultures of cerebellar
granule cells were treated with 100 ng ml–1
PDGF, 10 or 100 ng ml–1 NT-3, or 1 mg ml–1
bradykinin, in the presence or absence of
1 mg ml–1 766Tyr-P peptide, as described for
FGF in Fig. 2. The results show the
accumulation of IPs (see Materials and
methods), expressed as a percentage
increase over the control value, for the given
number of independent experiments. Bars
show the SEM. C, control.
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the peptide into the entire cell population in a repro-
ducible manner. There seems little doubt that the best
peptide inhibitor would be one that would freely cross
biological membranes.
In the present study, we wanted to develop a reagent that
would inhibit the activation of PLCg by FGF. In order to
do so, we took advantage of the fact that the activation of
this enzyme requires that it first binds to a high-affinity
site on the activated FGFR, and the observation that pep-
tides corresponding to this site compete for receptor
binding in vitro (see above). In order to deliver this
peptide into cells we made a tandem peptide that also
contained a 16 amino-acid sequence that will not only
cross membranes [15], but will also carry other peptides
[16] and antisense oligonucleotides [26] into cells. We
found that this peptide inhibited IP accumulation stimu-
lated by FGF, with a maximal inhibition at around
1mg ml–1 of the peptide. It was essential that 766Tyr was
phosphorylated in order for the peptide to inhibit the
response, in accord with the fact that phosphorylation is
required for the binding of PLCg to the FGFR [1,7–9].
The lack of inhibition by the unphosphorylated peptide is
unlikely to reflect a failure of this peptide to translocate
across the cell membrane as it carries less charge than the
phosphorylated peptide and would be expected to be
more soluble in the lipid bilayer; the presence of this
peptide in cells was also confirmed by microscopy (data
not shown).
PLCg contains two SH2 domains, one at the carboxyl ter-
minus and the other at the amino terminus. Binding
studies with randomized peptides suggest that these
domains display different sequence specificities [11]. The
FGFR has only one site that binds PLCg, and this site is
Figure 5
Stimulation of neurite outgrowth by basic FGF and inhibition by the
766Tyr-P peptide. Cerebellar neurons were cultured in media
supplemented with 10 ng ml–1 FGF alone, or FGF plus the 766Tyr-P
peptide (766Y-P) at 0.1 or 1mg ml–1, or the unphosphorylated peptide
(766Y) at 1 mg ml–1. After 16 h, the cultures were fixed and the mean
length of the longest neurite determined as described previously [23].
The results show the absolute increase in mean neurite length over the
value measured in cultures maintained in control media (31 ± 3 mm,
mean ± SEM from 20 independent experiments) in the given number
of experiments. Bars show the SEM. At 10 mg ml–1, the peptides had
no effect on basal neurite outgrowth in control cultures, the measured
value being 37 ± 2 mm and 33 ± 2 mm for the phosphorylated and
unphosphorylated peptide, respectively (both values are mean ± SEM
from three independent experiments).
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Figure 6
Effects of pre-treatment with the 766Tyr-P peptide on neurite outgrowth
stimulated by FGF and arachidonic acid (AA). Cerebellar neurons were
pre-treated with control media (DMEM) or DMEM containing the
766Tyr-P peptide at 100 mg ml–1 for 60 min prior to plating out into the
culture chambers. The neurons were then cultured for 16 h in media
supplemented with 5 ng ml–1 FGF or 10 mM AA. After 16 h, the
cultures were fixed and the mean length of the longest neurite
determined. The results show the absolute increase over the value
measured for neurons grown in control media (40.3 ± 1.0 mm, mean 
± SEM from six independent experiments) in the given number of
experiments. Bars show the SEM. Pre-treatment with the peptide had
no effect on basal neurite outgrowth (38.6 ± 0.8 mm; mean ± SEM
from six independent experiments).
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almost identical to the optimal sequence for binding to the
amino-terminal SH2 domain [11]. However, it has not
been determined whether the FGFR binds PLCg via its
amino- or carboxy-terminal SH2 domain, and it is not pos-
sible to say with certainty which domain the 766Tyr-P
peptide would be expected to bind to. Likewise, it is as
yet unclear whether one or both of the SH2 domains on
PLCg are used to interact with the other receptors that
activate this enzyme. It is difficult to predict whether the
peptide that corresponds to the high-affinity binding site
on the FGF receptor might also be expected to compete-
out binding of PLCg to other activated receptor tyrosine
kinases, and this is something that is probably best tested
for each receptor. In this context, we found that at
1 mg ml–1 the 766Tyr-P peptide did not inhibit a PDGF
response, nor did it inhibit an NT-3 response. In both
cases, a large body of evidence suggests that PLCg is acti-
vated following binding to defined phosphotyrosine
residues in the activated receptors (the PDGF receptor
and the TrkB and/or TrkC receptor) [6,11,13,19,20].
These data raise the interesting possibility that peptides
derived from individual receptor tyrosine kinases might
be able to be developed as agents that will specifically
inhibit the ability of that receptor to activate a down-
stream signalling cascade, although a considerable amount
of work will be required to fully test this hypothesis.
Here, we have taken the sequence of a known high-affin-
ity binding site for PLCg, introduced it into cells, and
found that it does indeed inhibit the activation of PLCg
by the activated FGFR. In many instances, it has not yet
been established which phosphotyrosine in a receptor
actually represents the physiological binding site for
PLCg. The results of the present study suggest that this
might easily be determined by testing the relative abilities
of a panel of phosphorylated peptides, derived from candi-
date sequences of the receptor, for their ability to inhibit
IP accumulation. It follows that this approach can also be
adopted for studying the binding of other signalling com-
ponents to a range of receptors. This will clearly comple-
ment the more conventional methods of site-directed
mutagenesis that were used to identify the PLCg-binding
site on the FGFR [8,9].
The development of cell-permeable peptides that inhibit
activation of an effector molecule allows one to test
whether that effector molecule is required for functional
responses in cells. FGF has a wide range of biological
activities that include modulation of cell phenotype, stim-
ulation of cell division and stimulation of axonal growth
[23,27–30]. Based on the expression of mutated receptors
that no longer bind PLCg, it has been suggested that acti-
vation of PLCg is not required for mitogenic responses
[8,9], or for neuronal differentiation of PC12 cells [31].
However, by the very nature of the experimental para-
digm, these results apply only to a situation where receptor
number is artificially high as a consequence of the overex-
pression of transfected FGFRs. Furthermore, in the case
of PC12 cells, the neurite outgrowth assay used as an index
of differentiation required a transcription-dependant
change in the cell from an adrenal to neuronal phenotype
[32]; the results with PC12 cells might not be pertinent,
therefore, to FGF-stimulated neurite outgrowth from dif-
ferentiated neurons. Based on a series of pharmacological
perturbations, it has been suggested that FGF stimulated
neurite outgrowth from cerebellar granule cells can be
fully accounted for by the activation of PLCg [23]. In the
present study, we tested this by determining whether the
766Tyr-P peptide could inhibit this response. It was found
that the presence of the peptide in the media, or indeed
pre-treatment of neurons with the peptide, inhibited the
growth response. Inhibition was apparent over the same
concentration range as that required to inhibit the IP accu-
mulation, and again was shown to be absolutely dependent
on the phosphorylation status of 766Tyr in the peptide.
The peptide did not inhibit the neurite-outgrowth
response stimulated by arachidonic acid, which is a down-
stream component of the signalling cascade, confirming
that it was acting at the right place in the pathway and
demonstrating that it had no non-specific effects on cell
viability or general neurite outgrowth. These data there-
fore support our previous conclusion that activation of
PLCg is both necessary and sufficient to account for the
FGF stimulation of neurite outgrowth from cerebellar
granule cells. 
Based on what we know about the FGFR signal transduc-
tion cascade (see above), the most parsimonious explana-
tion from the IP accumulation data and the studies on
neurite outgrowth is that the 766Tyr-P peptide acts by
inhibiting the association of PLCg with the activated
FGFR; it will be important to confirm this conclusion,
however, by immunoprecipitating the FGFR from control
and activated neurons. Likewise, although there are no
reports of other SH2 domain interactions with this region
of the FGFR, if these were to exist it follows that the
766Tyr-P peptide might also compete for their binding to
the receptor. In this context, the wealth of additional evi-
dence implicating activation of PLCg in the signal trans-
duction cascade underlying the neurite-outgrowth
response stimulated by FGF [23], and the fact that the
766Tyr-P peptide does not inhibit the arachidonic acid
response (see above), suggests that it is extremely unlikely
that the peptide is inhibiting neurite outgrowth by block-
ing an unknown SH2 domain interaction with the FGFR.
Conclusions
This study describes a peptide that inhibits the ability of
FGF to stimulate phospholipid hydrolysis, in the absence
of any effect on stimulation of the same response by three
other growth factors. To our knowledge, this is the first
time that such a highly specific reagent has been produced
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for use with living cells. Using this reagent, we have
obtained direct evidence that neurite outgrowth stimu-
lated by basic FGF requires activation of PLCg. By taking
advantage of the internalization properties of the third
helix peptide of the Antennapedia protein, and the known
identity of the binding sites on receptors for a range of
adaptor or signal transducing molecules, this study sug-
gests that a novel family of peptides can be designed for
use as tools for studying the biological consequences of
receptor activation.
Materials and methods
Production of synthetic peptides
Peptides were synthesized on a 431A Applied Biosystem peptide syn-
thesiser using p-Hydromethylphenoxy methyl polystyrene (HMP) resin
and standard Fmoc chemistry. Two peptides were used: RQIKIWFQNR-
RMKWKK, which corresponds to the 16 amino-acid sequence of the
third helix of the homeodomain of the Antennapedia protein (underlined);
and, in tandem, a nine amino-acid sequence, SNQEYLDLS, which corre-
sponds to the PLCg binding site on the FGF receptor (see text for
details). A phosphorylated Fmoc tyrosine (Novabiochem) was used to
make one of the peptides and this residue, shown in bold in the
sequence, corresponds to 766Tyr in the FGFR. This peptide is referred to
as the 766Tyr-P peptide. Peptides were analysed for purity by analytical
high-pressure liquid chromatography, and in both instances single peaks
were observed. The peptides were desalted on a Sephadex G10 column
(Pharmacia) and lyophilized. The peptides were made as stock solutions
at 20 mg ml–1 in dH2O and these stocks stored frozen at –20 °C. 
Peptide uptake into cells
The uptake of biotinylated peptides into cells was monitored as
described previously [15,16]. In brief, cultures of cerebellar neurons
were established overnight on polylysine (PL) coated wells of an 8-
chamber tissue culture slide [23]. The cultures were washed and media
replaced with DMEM containing 10 mg ml–1 of the 766Tyr-P peptide
biotinylated by standard methods [17] or a control biotinylated peptide
from the third helix of the Antennapedia protein that does not get taken
up into cells (see [15] for details). After 2 h, the cultures were washed
three times with tissue culture media, and fixed and permeabilized with
ethano:acetic acid (9:1 by volume) for 5 min at –20 °C. Non-specific
protein binding sites were blocked by incubating the cultures for 30 min
with Tris-buffered saline (TBS) containing 10 % fetal calf serum (FCS)
and 0.02 % Tween. The cultures were then incubated in the same
buffer containing FITC-conjugated Streptavidin (from Amersham at
1:200 dilution). The cultures were washed a further three times in TBS
before being mounted for viewing by confocal microscopy.
IP accumulation in cultures of cerebellar granule neurons
Cultures of small cerebellar neurons from postnatal day 1 rat pups were
established as described previously [33] and IP accumulation deter-
mined using standard procedures [34]. Briefly, 500 000 single cells from
the dissociated cerebellum were cultured in individual wells of a 6-well
tissue culture plate (NUNC) that had been coated with PL at 0.1 % in
dH2O. In order to label the membrane lipids, the cultures were grown for
16 h in DMEM supplemented with 10 % FCS in the presence of 1mCi
[3H]myo-inositol (Amersham), washed three times with DMEM and pre-
incubated for 30 min in DMEM containing 20 mM LiCl (DMEM–LiCl).
The cultures were then incubated for 60 min in DMEM–
LiCl and 10 mg ml–1 heparin (from Sigma) or in the same media supple-
mented with 100 ng ml–1 basic FGF (from Amersham) in the presence
and absence of the synthetic peptides as described in the text. At the
end of the 60 min incubation, ice-cold TCA was added (10 %) and the
IPs extracted for 30 min at 8 °C. TCA extracts were collected and the
dishes washed a further three times with 0.5 ml dH2O. After adjusting
the pH to 7.4 with 1 M NaOH, the samples were applied to a 0.5 ml bed
of AG-1-X8 resin (formate form from BioRad). The columns were
washed with 6 ml dH2O, 1 ml 50 mM NaBO4/60 mM ammonium
formate buffer followed by the elution of the total IP fraction with 1 ml of
1 M ammonium formate, 0.1 M formic acid. The eluted samples were
carefully mixed with 4 ml scintillation fluid (Aquasol, Packard, UK) and left
for at least 2 h before counting the radioactivity. Duplicate values were
determined for each condition in individual experiments, and the mean of
this value pooled for the given number of independent experiments.
Analysis of neurite outgrowth
In one set of experiments, dissociated cerebellar neurons from post-
natal day 1 rat pups (see [23] for full details) were plated at a density of
10 000 cells per individual well of an 8-chamber tissue culture slide
(Lab-TekR) that had been coated only with PL (see above). Cells were
cultured in DMEM supplemented with 10 % FCS for 16 h in media
further supplemented with FGF (10 ng ml–1) and/or synthetic peptides
as indicated. In a second set of experiments, dissociated neurons
obtained from postnatal day 2–4 rat pups were resuspended in DMEM
in the presence and absence of the 766Tyr-P peptide at 100 mg ml–1.
After 60 min, the peptide was removed from the media by washing the
cells three times with DMEM. The neurons were then plated at a
density of 6 000 cells per individual well of an 8-chamber tissue culture
slide that had been coated with PL followed by laminin [23]. The cul-
tures were grown for 16 h in DMEM/SATO medium supplemented with
2 % FCS. Both sets of cultures were fixed and immunostained for
GAP-43 as described previously [23]. The length of the longest neurite
on immunopositive cells was determined for approximately 150–200
neurons sampled from replicate cultures in each individual experiment.
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